A molecular key that breast cancer cells use to invade bone marrow has been identified in mice by scientists at the Duke Cancer Institute. Once inside the marrow, they can be protected from chemotherapy or hormonal therapies that could otherwise eradicate them.
Through years of experiments in mice, the scientists have found ways to outmaneuver this stealth tactic by not only preventing breast cancer cells from entering the bone marrow, but also by flushing cancer cells out into the blood stream where they could be targeted for destruction.
These findings shed light on one of the most devastating tendencies of some breast cancers, the ability to return after seemingly being vanquished. The researchers hope the findings, if replicated in additional animal and human tests, could eventually lead to new therapies for treating breast cancer.
E-selectin Molecular Key
Dorothy A. Sipkins, M.D., Ph.D., associate professor in the division of hematological malignancies and cellular therapy at Duke, says:
“Clinical studies have found that breast cancer can be caught early and treated, and patients can have no signs of disease. And then five, 10 or even 15 years later, a patient can relapse. Most often, the site of the metastasized cancer is in the bone.”
In their recently published paper, the researchers describe how cells from breast cancers that are hormone receptor-positive roam through the blood and tissues of mice. They’re hunting for specific blood vessels in bone marrow that contain the molecule E-selectin.
With their molecular key, molecules on their surface that bind to E-selectin, the cancer cells enter the spongy tissue inside bones, often lying dormant for years.
Roaming Cancer Cells
In human patients, these dormant cells can resurge later and create metastatic cancer relapse, for which there is no cure, said Sipkins, who is the paper’s senior author.
Biopsies of bone marrow in human breast cancer patients have shown that even at very early stages of the cancer, roaming cancer cells, or micrometastases, are making their way out of the breast and into the bone marrow, Sipkins said.
“Now we know how they are getting in,” she said. “We also identified an important mechanism that allows them to remain anchored in the bone marrow. In the mouse, our findings could offer new strategies to intervene at the molecular level before dormant cells can take hold and cause relapse.”
One strategy is finding a way to inhibit E-selectin, which could limit the cancer’s ability to travel into the bone and resurge as metastatic cancer, she said.
The scientists used an E-selectin inhibitor called GMI-1271, which is currently in human clinical trials. They found the compound successfully prevented the breast cancer cells from entering the bone marrow in mice.
Because microscopic metastases can spread to the bone marrow before patients are even diagnosed with breast cancer, the researchers also tested a strategy that appears to kick dormant breast cancer cells out of their safe house in the bone marrow and back into circulation. They gave the mice plerixafor, an agent used in human bone marrow donors to push stem cells into the bloodstream for harvesting.
The drug was able to force dormant breast cancer cells out of the bone tissue into the bloodstream.
The researchers hypothesize that flushing these dormant cancer cells back into the bloodstream might give the immune system, chemotherapy or hormonal therapy another opportunity at killing them off, Sipkins said. She and colleagues hope to investigate that approach further.
“We are hopeful that by understanding how these breast cancer cells migrate through the body and what their life cycle is, we can discover ways to make them more vulnerable and treatable,” Sipkins said. “Our hope is to move forward with additional studies in mice to better understand our approach before moving on to studies in humans.”
Trevor T. Price, et al.
Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone
Science Translational Medicine25 May 2016 : 340ra73
Top Image: Ed Uthman/Flickr
Did you like this article? Then you'll really want to sign up for my newsletter. It's delivered several times a week and packed with science news and analysis, stuff you won't easily find anywhere else on the web. Subscibe Here.